Scottsdale/Phoenix, AZ; La Crosse, WI; Eau Claire, WI; Mankato, MN
The proposed randomized controlled trial (RCT) for individuals with symptomatic knee OA is innovative. No trial has examined the optimal dosing interval for ultrasound guided dextrose prolotherapy intraarticular knee injections. This will give guidance to practitioners on the best frequency of dextrose prolotherapy to achieve symptomatic and functional improvements in knee OA patients. It also could give guidance to future studies of other regenerative products such as PRP for symptomatic knee OA and utilize DPT as the comparator treatment in a matched protocol.